Biofrontera (B8FK) AI Stock Analysis

3 Followers

Biofrontera

(XETRA:B8FK)

Select Model

Rating:51Neutral

Price Target:EUR 3.00▲(0.00% Upside)

Action:reiterated

Date:10/06/26

The score is held back primarily by weak financial performance—ongoing net losses and multi-year negative operating/free cash flow—despite low debt levels and strong gross margins. Technicals are a meaningful positive, with price above major moving averages and positive momentum indicators. Valuation remains a secondary drag due to the negative P/E and lack of dividend yield data.

Positive Factors

Strong Gross MarginThe approximately 83% gross margin indicates that Biofrontera’s products retain substantial value after direct production costs. If revenue stabilizes, this cost structure could support operating leverage, allowing incremental product sales to contribute more meaningfully toward covering commercial, research, and administrative expenses.

Negative Factors

Revenue VolatilityThe sharp post-2023 revenue decline and only modest 2025 recovery show that Biofrontera has not yet established consistent commercial momentum. Continued volatility makes capacity planning and expense absorption more difficult, while limiting confidence that the current portfolio can reliably support sustainable growth.

Biofrontera (B8FK) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 138.62M
Dividend Yield: ―
Average Volume (3M): 1,486
Price to Earnings (P/E): -1.5
Beta (1Y): 0.06
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 62
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Biofrontera Business Overview & Revenue Model

Company Description

Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the Unite...

How the Company Makes Money

Biofrontera makes money primarily by selling prescription dermatology products and associated photodynamic therapy (PDT) equipment into clinical channels. The core revenue stream historically has been product sales of Ameluz (topical gel used as a ph...

Biofrontera Earnings Call Summary

Earnings Call Date:Jun 03, 2026(Q1-2026)|% Change Since:18.58%|Next Earnings Date:May 29, 2019

Earnings Call SentimentPositive

The call presented meaningful operational and clinical progress: double-digit revenue growth (17% YoY), a substantial gross margin expansion to ~80% following the strategic transaction, near-breakeven operating cash usage ($70k), strong clinical/regulatory milestones (sNDA accepted with PDUFA date, positive Phase III AK data, encouraging acne Phase II), and regained NASDAQ compliance. Offsetting these positives are persistent GAAP losses (net loss $4.8M), higher SG&A (up ~27%), patent/legal and manufacturing transition costs, modest cash reserves ($6.3M) with a going concern qualification, and exposure to tariff/supply risks. Overall, the highlights—particularly the margin improvement, cash-flow progress, and clinical/regulatory advances—meaningfully outweigh the lowlights, though execution and financing risks remain.

Positive Updates

Revenue Growth

Product revenues of $10.1M in Q1 2026, up ~17% versus $8.6M in Q1 2025, driven by ~16% Ameluz unit volume growth and a price increase implemented in Q4 2025 (price increase contributed ~ $0.2M).

Negative Updates

Net Loss and GAAP Earnings Pressure

Net loss widened to $4.8M (loss per share $0.41) in Q1 2026 versus $4.2M (loss per share $0.47) in Q1 2025, reflecting nonrecurring items and a $0.8M swing in fair value of warrant liabilities that adversely impacted GAAP results.

Company Guidance

Management guided a 2026 path to cash‑flow breakeven supported by Q1 results: product revenues $10.1M (+17% YoY from $8.6M), Ameluz volumes ~29,000 tubes (+16% from ~25,000), a Q1 price lift that added ~$0.2M, 32 RhodoLED lamps shipped (installed base ~773 lamps in 709 offices), and a gross margin of ~80% (vs ~62% YoY) driven by a ~40% decline in cost of goods ($3.1M to $1.8M) and a $1.2M earnout (earnout terms: 12% of net sales ≤ $65M, 15% > $65M); financials also showed adjusted EBITDA of -$3.6M (margin -35% vs -51%), operating loss $4.3M, net loss $4.8M ($0.41/sh), cash used in operations ~$70k (vs $4.1M), cash $6.3M (vs $6.4M), a $3.4M AR collection, expectation to file an sNDA for AK in Q3, a sBCC PDUFA on Sept 28, 2026, and a long‑term gross margin target of 80–85% (patent protection through 2043).

Biofrontera Financial Statement Overview

Summary

Financials are pressured by weak profitability and cash burn. Revenue has been volatile with a sharp drop after 2023 and only a modest rebound in 2025. Despite strong gross margin (~83% in 2025) and low leverage (debt-to-equity ~0.04), the company remains net-loss making (net margin ~-30%) and free cash flow is negative (~-4.45M), increasing funding risk if conditions do not improve.

Income Statement

38Negative

Balance Sheet

67Positive

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	32.25M	13.19M	12.18M	32.25M	25.74M	28.79M
Gross Profit	26.00M	10.91M	10.12M	25.37M	20.98M	24.87M
EBITDA	-172.00K	-560.00K	-301.00K	5.57M	2.34M	-12.59M
Net Income	-369.00K	-3.96M	-4.35M	-369.00K	-44.17M	37.75M
Balance Sheet
Total Assets	30.73M	20.64M	30.15M	30.73M	32.73M	76.13M
Cash, Cash Equivalents and Short-Term Investments	3.08M	3.62M	3.28M	3.08M	6.38M	6.91M
Total Debt	1.15M	626.00K	765.00K	1.15M	1.50M	3.30M
Total Liabilities	10.75M	5.80M	11.30M	10.75M	12.39M	18.70M
Stockholders Equity	19.98M	14.90M	18.86M	19.98M	20.34M	57.43M
Cash Flow
Free Cash Flow	772.00K	-4.45M	-2.75M	-2.83M	-4.88M	29.81M
Operating Cash Flow	772.00K	-4.40M	-2.54M	-1.92M	-3.90M	30.44M
Investing Cash Flow	0	5.33M	-210.00K	-912.00K	-981.00K	-42.26M
Financing Cash Flow	0	-452.00K	2.79M	-467.00K	4.34M	2.18M

Biofrontera Technical Analysis

Technical Analysis SentimentNeutral

Last Price3.00

Price Trends

50DMA2.99Positive

100DMA2.72Positive

200DMA2.62Positive

Market Momentum

MACD-0.01Positive

RSI49.19Neutral

STOCH44.32Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:B8FK, the sentiment is Neutral. The current price of 3.00 is below the 20-day moving average (MA) of 3.02, above the 50-day MA of 2.99, and above the 200-day MA of 2.62, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 49.19 is Neutral, neither overbought nor oversold. The STOCH value of 44.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:B8FK.

Biofrontera Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:B8FK against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:EUZ	69Neutral	EUR 871.66M	18.13	19.49%	1.52%	4.05%	―
DE:MRK	68Neutral	EUR 65.91B	27.18	8.08%	1.48%	-0.40%	-17.22%
DE:DMP	65Neutral	EUR 1.91B	12.62	22.38%	2.52%	0.39%	38.58%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:B8FK	51Neutral	EUR 18.29M	-1.54	-127.78%	―	―	―
DE:EVT	50Neutral	EUR 561.41M	-3.07	-25.63%	―	-5.03%	-13.63%
DE:HPHA	41Neutral	EUR 99.18M	-3.19	200.64%	―	206.78%	-13.94%

* General Sector Average

Performance Comparison

DE:B8FK and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:B8FK	Biofrontera AG	3.00	0.33	12.36%
DE:EUZ	Eckert & Ziegler Strahlen und Medizintechnik	14.50	-1.54	-9.60%
DE:EVT	Evotec AG (UK)	3.12	-2.17	-40.95%
DE:MRK	Merck KGaA	148.15	32.91	28.56%
DE:HPHA	Heidelberg Pharma AG	2.04	-0.98	-32.45%
DE:DMP	Dermapharm Holding	34.95	1.19	3.51%

Biofrontera Corporate Events

Financial DisclosuresRegulatory Filings and Compliance

Biofrontera Sets Date for Release of 2026 Half-Year Results

Neutral

Sep 30, 2026

Biofrontera AG has announced the scheduled publication of its half-year financial report for 2026, covering the period from 1 January to 30 June 2026. The report is set to be released on 30 September 2026 and will be made available to investors via t...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 06, 2026

Biofrontera AI Stock Analysis